Lionco Pharmaceutical Group Co (SHSE:603669) Long-Term Debt: ¥17.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603669 Lionco Pharmaceutical Group Co Ltd SHSE:603669
55 GF Score
Price ¥5.48
GF Value ¥7.14
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Lionco Pharmaceutical Group Co Long-Term Debt?

Lionco Pharmaceutical Group Co SHSE:603669 -9.42% 55 Long-Term Debt is ¥17.0 Mil as of Jun. 2026. GuruFocus rates SHSE:603669 with a GF Score™ of 55/100 and a GF Value™ of ¥7.14 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Lionco Pharmaceutical Group Co's Long-Term Debt for the quarter that ended in Jun. 2026 was ¥17.0 Mil.

Lionco Pharmaceutical Group Co's quarterly Long-Term Debt increased from Dec. 2025 (¥0.0 Mil) to Mar. 2026 (¥18.0 Mil) but then declined from Mar. 2026 (¥18.0 Mil) to Jun. 2026 (¥17.0 Mil).

Lionco Pharmaceutical Group Co's annual Long-Term Debt declined from Dec. 2023 (¥439.3 Mil) to Dec. 2024 (¥258.0 Mil) and declined from Dec. 2024 (¥258.0 Mil) to Dec. 2025 (¥0.0 Mil).

Lionco Pharmaceutical Group Co  (SHSE:603669) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Lionco Pharmaceutical Group Co Long-Term Debt Related Terms

Lionco Pharmaceutical Group Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Lionco Pharmaceutical Group Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lionco Pharmaceutical Group Co Long-Term Debt Chart

Lionco Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 385.91 412.52 439.34 257.99 0.00

Lionco Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 268.10 273.21 0.00 18.00 17.00
SHSE:603669
55GF Score
Lionco Pharmaceutical Group Co Ltd SHSE:603669
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ¥17.0 Mil mean?
Lionco Pharmaceutical Group Co (SHSE:603669) has a Long-Term Debt of ¥17.0 Mil as of Jun. 2026.
Is Lionco Pharmaceutical Group Co's Long-Term Debt too high?
Lionco Pharmaceutical Group Co's current Long-Term Debt is ¥17.0 Mil. Overall, Lionco Pharmaceutical Group Co has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lionco Pharmaceutical Group Co's Long-Term Debt compare to ZTS?
Lionco Pharmaceutical Group Co's Long-Term Debt of ¥17.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Lionco Pharmaceutical Group Co's current Long-Term Debt is ¥17.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lionco Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Lionco Pharmaceutical Group Co (SHSE:603669) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.14, compared to a current price of ¥5.48 — trading 23.2% below its estimated fair value. The current Long-Term Debt is ¥17.0 Mil. Lionco Pharmaceutical Group Co's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Lionco Pharmaceutical Group Co (SHSE:603669), the current Long-Term Debt is ¥17.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lionco Pharmaceutical Group Co (SHSE:603669) Overvalued in 2026?

Based on GuruFocus' analysis, Lionco Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥5.48 is trading 23.2% below its estimated GF Value™ of ¥7.14. GuruFocus considers Lionco Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:603669:

  • Long-Term Debt: ¥17.0 Mil
  • GF Value™: ¥7.14 vs. price of ¥5.48 (23.2% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603669 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lionco Pharmaceutical Group Co Business Description

Address No. 20, National Highway 349, Naidong District, Shannan, CHN
Lionco Pharmaceutical Group Co Ltd is engaged in the research and development of medicines. The product portfolio includes - Alanyl glutamine for injection, fructose for injection, inverted sugar for injection, xylitol for injection, riboflavin sodium phosphate for injection, and water-soluble vitamin for injection.
55GF Score

Get the complete analysis for SHSE:603669

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.48
Price
¥7.14
GF Value